ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,000.00
-0.94%
Dow Jones
40,287.53
-0.93%
Brent Oil
81.875
0.00%
Bitcoin
66,644.45
-0.11%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. XOMA Royalty Corporation (XOMAP)

  7. XOMA Royalty Corporation (XOMAP) News

XOMAP

XOMA Royalty (XOMAP)

XOMA Royalty Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XOMAP
DateTimeSourceHeadlineSymbolCompany
07/09/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Royalty Corporation
06/20/20247:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAPXOMA Royalty Corporation
06/18/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XOMAPXOMA Royalty Corporation
06/18/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XOMAPXOMA Royalty Corporation
06/13/20244:31PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:XOMAPXOMA Royalty Corporation
06/12/20247:30AMGlobeNewswire Inc.XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review VoucherNASDAQ:XOMAPXOMA Royalty Corporation
05/30/20244:43PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Royalty Corporation
05/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Royalty Corporation
05/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Royalty Corporation
05/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Royalty Corporation
05/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Royalty Corporation
05/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Royalty Corporation
05/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Royalty Corporation
05/16/20247:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Royalty Corporation
05/14/20247:30AMGlobeNewswire Inc.XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQNASDAQ:XOMAPXOMA Royalty Corporation
05/09/20247:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Royalty Corporation
05/09/20247:35AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XOMAPXOMA Royalty Corporation
05/09/20247:30AMGlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAPXOMA Royalty Corporation
04/30/20247:30AMGlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAPXOMA Royalty Corporation
04/25/20247:30AMGlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAPXOMA Royalty Corporation
04/03/20249:00AMGlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAPXOMA Royalty Corporation
03/21/20247:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAPXOMA Royalty Corporation
03/19/20244:05PMGlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAPXOMA Royalty Corporation
03/11/20246:56AMEdgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:XOMAPXOMA Royalty Corporation
03/08/20244:34PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:XOMAPXOMA Royalty Corporation
03/08/20247:39AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Royalty Corporation
03/08/20247:30AMGlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAPXOMA Royalty Corporation
03/04/20245:24PMEdgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:XOMAPXOMA Royalty Corporation
02/28/20247:30AMGlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAPXOMA Royalty Corporation
02/16/20249:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Royalty Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMAP

Your Recent History

USOTC
VPLM
Voip Pal Com (QB)
USOTC
NBRI
North Bay Resources (PK)
USOTC
HIRU
Hiru (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
INQD
Indoor Harvest (CE)
USOTC
SPZI
Spooz (PK)
AMEX
SPY
SPDR S&P 500
USOTC
CNNA
Cann American (CE)
USOTC
AXXA
Exxe (PK)
COIN
BTCUSD
Bitcoin
USOTC
CGAC
Code Green Apparel (PK)
USOTC
BIEL
Bioelectronics (PK)
USOTC
ASKH
Astika (PK)
USOTC
RNVA
Rennova Health (CE)
NYSE
GME
GameStop
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved